Krishan Rattan.
The next healthcare revolution may be less about treating illness and more about identifying risk early enough to keep people healthy. Krishan Rattan believes the economic consequences could reach far beyond medicine.
Krishan Rattan has spent much of his career thinking about infrastructure. Increasingly, he believes human health should be thought about in similar terms.
Roads, energy systems and digital networks are valuable because they allow economies to function. Health performs a comparable role at the level of the individual. When people remain healthy, they work, travel, consume, care for families, create businesses and participate in society. When health deteriorates, the economic cost spreads quickly.
This is the lens through which the Terra Invest Founding Partner views longevity.
Not immortality. Not a collection of expensive anti-ageing treatments. A broad transition from reactive medicine toward earlier detection, more personalised intervention and longer healthspan.
"The investment case for longevity becomes much easier to understand once you stop thinking about age and start thinking about capability."
The distinction between lifespan and healthspan is central to Rattan's thesis. Medicine has become much better at keeping people alive. The next challenge is increasing the number of those years in which people remain physically strong, cognitively sharp and independent.
That goal touches an unusually large set of industries. Diagnostics, imaging, genomics, metabolic medicine, cardiovascular prevention, oncology screening, regenerative therapies, digital health, wearable sensors, nutrition, sleep and AI can all play a role.
It also means longevity is unlikely to be controlled by one company or one breakthrough. It is better understood as a new layer across healthcare.
Rattan comes to the subject as a capital allocator rather than a scientist. Terra Invest's published biography says he has raised, deployed and overseen more than US1.2 billion in AUM.
That background makes him particularly interested in industries where fragmented assets can become platforms and where technology changes the economics of an existing service.
Healthcare appears to be entering precisely that phase. The data already exists in pieces: blood tests, imaging, medical history, genetics, wearables, prescriptions, sleep patterns and lifestyle information. What is missing is often the connective layer that turns those signals into a continuously updated picture of risk.
"Healthcare has an enormous amount of information. The opportunity is to make that information more connected, more usable and available earlier in the decision process."
The promise of personalised medicine has existed for years, but the economics have been difficult. A highly personalised service requires specialist attention, and specialist attention does not scale easily.
AI changes the equation because it can assist with the continuous interpretation of large data sets. It can help identify changes, prioritise anomalies and surface patterns for clinicians to review.
Rattan is careful about the distinction between assistance and replacement. He believes the most compelling healthcare models will combine human clinical expertise with increasingly capable decision-support systems.
"I am much more interested in the idea of an excellent doctor augmented by technology than in a narrative where technology eliminates the doctor."
Technology alone will not determine adoption. Healthcare delivery itself has to change.
Many medical systems remain organised around institutions rather than individuals. Patients move between departments, clinics, laboratories and specialists, often carrying fragmented information between them. Preventive healthcare works better when the relationship is continuous.
This is why Terra Invest is interested not only in biotech and diagnostics, but in the service layer around longevity. Through the 2100 Group ecosystem and healthcare initiatives including Shookra Clinics, the group is exploring a more integrated model spanning diagnostics, clinical care, performance, regenerative medicine, telehealth and concierge support.
The ambition is to make healthcare feel less like a sequence of isolated appointments and more like an intelligently managed long-term system.
Sport offers a useful precedent. Elite athletes have long treated their bodies as data-rich systems. They monitor sleep, recovery, training load, nutrition, injury risk and performance. They intervene before a small problem becomes a season-ending one.
Rattan believes some of that mentality is moving into mainstream medicine. The objective is not to turn everyone into a professional athlete, but to borrow the basic principle: measure earlier, understand baselines and respond to deterioration before it becomes severe.
"The most interesting shift is from asking âwhat disease do you have?' to asking âwhat is changing in your health, and can we do something about it now?'"
The UAE has several advantages in building this category. It has a globally mobile population, sophisticated private healthcare, strong hospitality and aviation links, significant investment capital and governments that have made AI and health innovation strategic priorities.
It is also positioned to serve international clients. For a premium preventive-health platform, the addressable market does not end at the city boundary. Dubai and Abu Dhabi can function as regional hubs for people travelling from the Middle East, South Asia, Europe and Africa.
Rattan believes the same ecosystem can eventually support research, clinical partnerships, technology companies and investment capital, creating something larger than medical tourism.
The longevity sector inevitably attracts futuristic claims. Rattan thinks investors should be able to hold excitement and scepticism at the same time.
There may be genuine breakthroughs in regenerative medicine and the biology of ageing. But a meaningful portion of the longevity dividend may come from interventions that are already familiar: preventing diabetes, improving cardiovascular health, detecting cancer earlier, preserving muscle and bone, improving sleep and making patients more consistent about preventive care.
That is commercially important because it means the opportunity does not depend entirely on a future scientific breakthrough.
The final part of Terra Invest's thesis is macroeconomic. If a large population remains healthy for longer, the effects extend into pensions, insurance, employment, travel, housing, financial services and consumer behaviour.
People may work differently. Retirement may become more flexible. Older consumers may remain active for longer. Employers may invest more aggressively in prevention because experienced talent remains productive.
"Adding healthy years is not only a medical outcome. It is an economic outcome."
That is why Rattan believes longevity could ultimately become comparable to other structural investment themes that began inside one sector and then spread across many.
The promise is not that everybody lives forever. It is much more practical: that a larger share of a longer life can remain a good life. For Terra Invest, that is already big enough to build an investment thesis around.
